We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Two-Gene Test Differentiates Psoriasis from Eczema

By LabMedica International staff writers
Posted on 23 Jul 2014
Print article
Image: Large plaque psoriasis of the limbs (Photo courtesy of the American Academy of Dermatology).
Image: Large plaque psoriasis of the limbs (Photo courtesy of the American Academy of Dermatology).
Previous attempts to gain insight into the pathogenesis of psoriasis and eczema by comparing their molecular signatures were hampered by the high inter-individual variability of those complex diseases.

Although it is possible to distinguish classical plaque-type psoriasis from typical atopic eczema, in daily clinical practice, discrimination is often challenging because psoriasis and eczema phenotypes might overlap or mimic each other.

Scientists at the Helmholtz Zentrum München (Munich, Germany) and their colleagues investigated the molecular signature of psoriasis and eczema, using psoriasis and eczema tissue samples from 24 patients who had both diseases. The cohort for the validation of the disease classifier consisted of 25 patients with psoriasis, with a mean age of 47 ± 13 years and 60% were female and 28 patients with eczema with a mean age 35 ± 15 years and 64% were female. Skin punch biopsies were obtained under local anesthesia from either one eczema lesion or one psoriasis plaque, and clinically noninvolved skin of all patients.

Biopsies were divided for routine histologic evaluation and isolation of total ribonucleic acid (RNA). The RNA yield and quality were determined with a NanoDrop ND1000 UV-Vis Spectrophotometer and the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Whole-genome expression array fluorescence signals were detected by reading the arrays in the Agilent Technology microarray scanner system iScan. Real-time polymerase chain reactions (PCRs) were performed in 384-well plates and analyzed on the ViiA 7 Real Time PCR machine (Applied Biosystems; Foster City, CA, USA).

Among other differences that the investigators found, for example, genes specific to psoriasis were important regulators of glucose and lipid metabolism, while genes specific to eczema related to epidermal barrier and reduced innate immunity. From further analysis they selected two genes—nitric oxide synthase 2 (NOS2) and Chemokine (C-C Motif) Ligand 27 (CCL27)—that they considered would make a reliable classifier of disease. They then showed, with the validation group of patients, that a test using the two genes was able to diagnose all 28 eczema and 25 psoriasis cases correctly. The test also identified initially misdiagnosed or clinically undifferentiated patients, with the two-gene test producing results within a day.

The authors concluded that the two-gene classifier identifies the correct diagnosis with a high accuracy, and their initial results suggest that it might be superior to gold standard techniques such as clinical evaluation and histology, and will also save time and money. In recent years many new specific treatments have been developed for psoriasis and eczema, but they are only effective for the target disease, and they are expensive. Therapeutic strategies for psoriasis and eczema are distinct and sometimes opposing, so this diagnostic tool could be valuable to set the correct diagnosis in special cases. The study was published on July 9, 2014, in the journal Science Translational Medicine.

Related Links:

Helmholtz Zentrum München

Agilent Technologies

Applied Biosystems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.